Human RCTPubMed ID: 37622681·2023

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.

New England Journal of Medicine, 2023 · n = 529

Key finding

Semaglutide improved heart failure symptoms, 6-minute walk distance, and produced 13.3% weight loss in patients with HFpEF — a condition with very few effective treatments.

Summary

Trial showing semaglutide significantly improved heart failure symptoms, exercise capacity, and weight in patients with HFpEF and obesity.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

JAMA Cardiology · 2022 · Human Pilot